Phoenix Rising tells QMUL: release the PACE trial data
Mark Berry, Acting CEO of Phoenix Rising, presents the Board of Directors’ open letter to Queen Mary University of London (QMUL) urging them to release the PACE trial data, and hopes that other non-UK organisations will join British charities in the same request...
Discuss the article on the Forums.

ATA188, Which Kills B-Cells Targeting Epstein-Barr Virus, Shows Promise as MS Treatment

Discussion in 'Other Health News and Research' started by Webdog, May 2, 2017.

  1. Webdog

    Webdog Up to 91% remain undiagnosed

    Very small Phase 1 trial of targeted B-cell therapy for multiple sclerosis patients. Perhaps those more knowledgeable could chime in on whether ME/CFS patients might one day benefit from some kind of targeted B-cell therapy.
    Atara Bio's press release:
    Gemini, Skippa, adelheid55 and 4 others like this.

See more popular forum discussions.

Share This Page